Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)

NCT00675623 is registered in ClinicalTrials.gov with Medivation, Inc. as lead sponsor.

NCT NCT00675623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00675623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)
Lead sponsor
Medivation, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2008
Completion date
Not reported
Enrollment
598 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease